Resilient CD8+ T cells maintain a high cytotoxic capacity by balancing ROS via ME1 upregulation
Gicobi,J. K.,Mao,Z.,DeFranco,G.,Li,Y.,Liu,C.,Hirdler,J. B.,Vianzon,V. V.,Dellacecca,E. R.,Hsu,M. A.,Barham,W.,Kim,Y. H.,Feven,A.,Harmsen,W. S.,Yan,Y.,Dronca,R. S.,Zhu,M.,Markovic,S.,Mansfield,A. S.,Lin,Y.,Wu,X.,Owen,D.,Grams,M. P.,Orme,J. J.,Lucien,F.,Zeng,H.,Park,S. S.,Dong,H.
DOI: https://doi.org/10.1101/2022.11.25.517988
2022-11-27
bioRxiv
Abstract:Cytotoxic T lymphocytes (CTL) are indispensable in anti-tumor immunity. Although CTLs are prone to exhaustion in patients with advanced cancer, T cell resiliency explains the presence of tumor-reactive CTLs that are less exhausted, capable of cytolytic function, expand, and rebound in response to immunotherapy to reject metastatic malignancies. However, the features of resilient T cells have not been clearly defined. In this report, we demonstrate peripheral CX3CR1+ CD8+ T cells with low mitochondrial membrane potential portray a functional resiliency in patients with large tumor burden as their CTL function rebounded quickly after radiation therapy. Furthermore, CX3CR1+ CD8+ T cell with low, but not high, mitochondrial membrane potential are highly cytotoxic, accumulate less reactive oxygen species (ROS) and express more Malic enzyme 1 (ME1). ME1 overexpression increases ATP production in a glycolysis-independent manner while concurrently curtailing excessive ROS in activated CD8+ T cells; and expands CX3CR1+NKG7+ effector CD8+ T cells with enhanced cytotoxicity. Importantly, transfection of ME1 mRNA promotes tumoricidal activity in CD8+ T cells from patients with advanced cancers. Our study reveals a mechanism used by CTLs to balance excessive ROS via ME1 to maintain a metabolic and functional resiliency. Modification of ME1 expression in CTLs may be a novel method to improve the efficacy of cancer immunotherapy by preventing T cell exhaustion.